Results 81 to 90 of about 27,075 (224)

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

BMC Cancer
Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD).
Qiyu Zhu, Junru Chen, Haoyang Liu, Jinge Zhao, Chenhao Xu, Guangxi Sun, Hao Zeng   +6 more
doaj   +1 more source

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

PARP inhibitor combinations with Olaparib for synergistic efficacy in Olaparib-resistant triple-negative breast cancer cells [PDF]

, 2023
Triple-negative breast cancer (TNBC) is associated with aggressive and heterogenous tumour phenotype, early tumour relapse and poor prognosis than other types of invasive breast cancer.
Yusoh, Nur Aininie
core   +1 more source

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer

, 2018
Min Wu,1,* Jing Liu,1,* ChuanFei Hu,1 Dong Li,1 Juan Yang,1 ZhouXue Wu,1 LingLin Yang,1 Yue Chen,2 ShaoZhi Fu,1 JingBo Wu1 1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China; 2Department of Nuclear ...
Wu Z, Wu J, Wu M, Liu J, Hu C, Yang J, Fu S, Yang L, Li D, Chen Y   +9 more
core  

Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ovarian cancer (OC) is one of the most prevalent and severe gynecological malignant tumors. DNA damage repair (DDR) is essential in maintaining genome stability. This study aims to investigate the effects and mechanisms of USP38 and PLK1 on DNA damage repair and malignant behavior in OC cells.
Yuan Ma, Ying Li, Kai‐Li Li
wiley   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan, Jiun‐Hung Geng, Hung‐Lung Ke, Shu‐Pin Huang, Li Jia   +4 more
wiley   +1 more source

The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model

BMC Pulmonary Medicine
Background Poly (ADP‒ribose) polymerase (PARP) is a constitutive enzyme involved in regulating various biological processes in health and disease. In the present study, we investigated the role of PARP1 in pulmonary fibrosis and assessed the efficacy of ...
Habtamu B. Derseh, Andrew N. Davies, Alarna Young, Sylvie Bischof, Joseph Pelle, David Rudd, Michelle McIntosh, David Piedrafita, Robert J. Bischof   +8 more
doaj   +1 more source

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy

, 2018
Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani, Francesco Raspagliesi Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy Abstract: Epithelial ovarian cancer is ...
Lorusso D, Tripodi E, Bogani G, Maltese G, Lepori S, Sabatucci I, Raspagliesi F   +6 more
core  

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer [PDF]

, 2020
BACKGROUND: We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had ...
Shore, Neal, PROfound Trial Investigators, Corcoran, C, Shore, N, Mateo, J, Fizazi, K, Sandhu, S., Fizazi, K., Roubaud, G., Sandhu, S, Roubaud, Guilhem, Kang, Jinyu, Saad, F, Olmos, David, Twardowski, P., Sartor, Oliver, Gresty, Christopher, Mehra, N., Hussain, M., Mateo, Joaquin, Özgüroğlu, M, Burgents, Joseph, Sartor, O, Olmos, D., Sandhu, Shahneen, Fizazi, Karim, Saad, Fred, de Bono, Johann, Adelman, Carrie A, Corcoran, Claire, Roubaud, G, Adelman, CA, Olmos, D, Gresty, C., Thiery-Vuillemin, Antoine, Thiery-Vuillemin, A, Özgüroğlu, Mustafa, Gresty, C, Burgents, J, Thiery-Vuillemin, A., Twardowski, P, Hussain, Maha, Chi, Kim N, Mateo, J., Burgents, J., Shore, N., Chi, KN, Özgüroğlu, M., Agarwal, N, de Bono, J, Chi, K.N., Sartor, O., Adelman, Caroline, Hussain, M, Agarwal, Neeraj, Twardowski, Przemyslaw, Corcoran, C., Kang, J., Kang, J, Saad, F., Bono, J. de, PROfound Trial Investigators,, Agarwal, N.   +62 more
core   +2 more sources

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source